Autoimmune Disease Therapeutics Market by Product, Application

Description

List of Tables

[197 Pages Report] The Autoimmune Disease Therapeutics Market size was estimated at USD 198.99 billion in 2023 and expected to reach USD 214.54 billion in 2024, at a CAGR 7.90% to reach USD 339.00 billion by 2030.

Global Autoimmune Disease Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023]	USD 198.99 billion
Estimated Year [2024]	USD 214.54 billion
Forecast Year [2030]	USD 339.00 billion
CAGR (%)	7.90%

Autoimmune Disease Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Autoimmune Disease Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Autoimmune Disease Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Autoimmune Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., BioAgilytix Labs, LLC, bioMerieux S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Exagen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi S.A., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Trinity Biotech PLC, UCB S.A., and Werfen S.A..

Market Segmentation & Coverage

This research report categorizes the Autoimmune Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Diagnostic Equipment
- Drugs
  - Aminosalicylates or 5-ASA
  - Anthralin
  - Avonex
  - Betaseron
  - Calicipotriene
  - Copaxone
  - Corticosteriods
  - Glucocorticoids
  - Hydroxychloroquine
  - Methotrexate
  - Non-steroidal Anti-inflammatory Drugs
  - Rebif
Application
- Localized Autoimmune Diseases
- Systemic Autoimmune Diseases
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Autoimmune Disease Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Autoimmune Disease Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Autoimmune Disease Therapeutics Market?

4. What is the market share of the leading vendors in the Autoimmune Disease Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Autoimmune Disease Therapeutics Market?

Product Code: MRR-030C42D3EDB8

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Autoimmune Disease Therapeutics Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing prevalence of autoimmune diseases across the globe
  - 5.1.1.2. Rapidly improvement in healthcare infrastructure coupled with rising patient awareness levels
  - 5.1.1.3. Automation of laboratories to ease several autoimmune diagnostic tests
- 5.1.2. Restraints
  - 5.1.2.1. High cost and uncertain outcomes of the treatment
- 5.1.3. Opportunities
  - 5.1.3.1. Increasing funding by government associations and non-profit organizations
  - 5.1.3.2. Emergence of target therapies for autoimmune disease
- 5.1.4. Challenges
  - 5.1.4.1. Side effects of autoimmune diseases immunotherapy
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Autoimmune Disease Therapeutics Market, by Product

6.1. Introduction
6.2. Diagnostic Equipment
6.3. Drugs
- 6.4.1. Aminosalicylates or 5-ASA
- 6.4.2. Anthralin
- 6.4.3. Avonex
- 6.4.4. Betaseron
- 6.4.5. Calicipotriene
- 6.4.6. Copaxone
- 6.4.7. Corticosteriods
- 6.4.8. Glucocorticoids
- 6.4.9. Hydroxychloroquine
- 6.4.10. Methotrexate
- 6.4.11. Non-steroidal Anti-inflammatory Drugs
- 6.4.12. Rebif

7. Autoimmune Disease Therapeutics Market, by Application

7.1. Introduction
7.2. Localized Autoimmune Diseases
7.3. Systemic Autoimmune Diseases

8. Americas Autoimmune Disease Therapeutics Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Autoimmune Disease Therapeutics Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Autoimmune Disease Therapeutics Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

12.1. Key Company Profiles
- 12.1.1. Abbott Laboratories
- 12.1.2. AbbVie Inc.
- 12.1.3. Amgen Inc.
- 12.1.4. AstraZeneca PLC
- 12.1.5. Beckman Coulter, Inc.
- 12.1.6. Bio-Rad Laboratories, Inc.
- 12.1.7. BioAgilytix Labs, LLC
- 12.1.8. bioMerieux S.A.
- 12.1.9. Bristol-Myers Squibb Company
- 12.1.10. Eli Lilly and Company
- 12.1.11. Exagen, Inc.
- 12.1.12. F. Hoffmann-La Roche Ltd.
- 12.1.13. GlaxoSmithKline PLC
- 12.1.14. Johnson & Johnson Services, Inc.
- 12.1.15. Lupin Limited
- 12.1.16. Merck & Co., Inc.
- 12.1.17. Novartis AG
- 12.1.18. Pfizer, Inc.
- 12.1.19. Sanofi S.A.
- 12.1.20. Siemens Healthineers AG
- 12.1.21. Thermo Fisher Scientific Inc.
- 12.1.22. Trinity Biotech PLC
- 12.1.23. UCB S.A.
- 12.1.24. Werfen S.A.
12.2. Key Product Portfolio

13. Appendix

13.1. Discussion Guide
13.2. License & Pricing